Rexin-G

BostonGene will showcase its AI-powered multiomics platform and its new immune system profiling platform, which stratifies cancer patients by treatment response WALTHAM, Mass.--(BUSINESS WIRE)-- BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that seven abstracts have been accepted for the 2024 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2024, at McCormick Place Convention Center in Chicago, IL. BostonGene will deliver one oral presentation and present two posters, while four abstract presentations will be available online. BostonGene will also exhibit at booth 22157. At the event, BostonGene will feature its AI-powered multiomics platform that rapidly accelerates new research and drug development while precisely matching each patient with the best available therapy. BostonGene will also highlight its recently announced immune system profiling platform, a novel classification method and a scoring system based on this classification of systemic immunity with patient responses to various cancer treatments. This diagnostic and analytical immune system profiling framework underscores the potential of a straightforward blood test, supported by additional clinical validation, as a tool to stratify cancer patients into responders and non-responders across different treatments. Details about the abstracts selected for presentation can be found below: Oral presentation Abstract: 2015 Title: A phase Ib, window-of-opportunity study of neoadjuvant avelumab and hypofractionated proton beam therapy for recurrent radiation-relapsed meningioma Date and time: Sunday, June 2, 2024 | 11:30 AM - 1:00 PM Speaker: Jiayi Huang, MD, Washington University School of Medicine This study evaluated the immunological effects of combining avelumab, an anti-PD-L1 inhibitor, with radiation therapy (RT) for recurrent radiation-relapsed meningioma. The use of RNA-seq and MxIF on pre- and post-avelumab tumor tissues revealed that for some patients the combination (avelumab + RT) may cause an immunological response leading to prolonged remission, warranting further larger prospective studies and biomarker investigations. Research done in collaboration with the Washington University School of Medicine Poster presentations Abstract: 11523 Title: Transcriptomic analysis of novel tumor suppressor gene fusions in bone sarcomas Date and time: Saturday, June 1, 2024 | 1:30 PM - 4:30 PM Poster: 449 Speaker: Nikita Kotlov, BostonGene Transcriptomic analysis of treated bone sarcomas revealed a unique breakpoint combination in an oncogene and previously unknown gene fusions involving tumor suppressor genes. These findings highlight the importance of RNA-seq to advance research and identify potential biomarkers for sarcomas. Research done in collaboration with The University of Texas MD Anderson Cancer Center, Massachusetts General Hospital Cancer Center and the Sarcoma Oncology Center Abstract: 1044 Title: The multiomic tumor microenvironment landscape of invasive lobular carcinoma of the breast Date and time: Sunday, June 2, 2024 | 9:00 AM - 12:00 PM Poster: 22 Speaker: Jason Mouabbi, MD, The University of Texas MD Anderson Cancer Center Multiomic analysis using integrated RNA-seq and MxIF uncovered the intricate heterogeneity of the tumor microenvironment (TME) in invasive lobular carcinoma (ILC) of the breast, emphasizing the critical role of comprehensive TME profiling to understand and develop personalized treatments for ILC. Research done in collaboration with MD Anderson Cancer Center Online-only abstracts Abstract: e13168 Title: Closing classification gaps in luminal breast cancer with single-cell RNA-seq insights from normal breast lineages In this study, single-cell RNA-seq was used to investigate the connection between breast cancer classification and luminal expression pro The findings showed that compared to other breast cancer subtypes, luminal breast cancers are less similar to most luminal epithelial clusters in normal breast tissue, which suggests that the complexity of luminal-type breast cancers is not captured by traditional breast cancer classification methods. Abstract: e15138 Title: Integrated genomic and transcriptomic characterization of neuroendocrine carcinomas for improved treatment decision-making Integrated whole exome (WES) and RNA sequencing (RNA-seq) detected unique molecular features across diverse neuroendocrine tumors, indicating the potential use of comprehensive molecular profiling for therapy and clinical trial matching to improve outcomes for neuroendocrine carcinoma (NEC) patients. Research conducted in collaboration with Advanced Cancer Treatment Centers, Mayo Clinic and Duke Cancer Institute Abstract: e13593 Title: An unsupervised H&E-based machine-learning approach for precise prediction of tumor microenvironment subtypes. This study describes the development of an H&E-based machine-learning approach using colorectal cancer (CRC) samples. The results show that the H&E-based approach complements next-generation sequencing (NGS) tumor microenvironment (TME) classification, suggesting that the advanced image analysis can help refine prognostic and therapeutic strategies for CRC and warrant further expansion to other cancer types. Abstract: e15086 Title: Effect of DeltaRex-G ± DeltaRex-G Plus (an FDA-approved drug) on advanced chemoresistant pancreatic cancer, sarcoma, and breast cancer This study investigated the use of DeltaRex-G, a CCNG1 inhibitor, administered either alone or in combination with an FDA-approved drug (DeltaRex-G Plus) in advanced cancers. RNA sequencing identified enhanced CCNG1 expression in all analyzed tumors and analysis showed that the five patients treated with DeltaRex-G Plus had a partial response or stable disease, supporting the use of DeltaRex-G Plus as a promising therapy. Research conducted in collaboration with City of Hope Comprehensive Cancer Center, Sarcoma Oncology Center, Duke University and Expression Therapeutics For more information, please visit the 2024 ASCO Annual Meeting website. The abstracts will be published online in the Journal of Clinical Oncology supplement for the ASCO Annual Meeting Proceedings. About BostonGene Corporation BostonGene is a company at the intersection of technology and biology, dedicated to advancing and personalizing cancer medicine. Founded in 2015, BostonGene has continually pushed the boundaries of innovation to improve cancer patient care and accelerate research and drug development through cutting-edge solutions. Leveraging our AI-powered multiomics platform, we digitize and comprehensively analyze the molecular profiles of cancer patients, including the immune system and tumor microenvironment. Our software solutions, indication-specific cancer library and advanced bioanalytics, enable us to discover multiparametric signatures, identify targets, match them to relevant indications for biopharma and recommend the most effective treatments for patients. For more information, visit .

WALTHAM, Mass.--( BUSINESS WIRE )-- BostonGene , a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center , announced a collaboration to expedite the availability of DeltaRex-G. This groundbreaking platform therapy, authorized by the FDA's Center for Biologics Evaluation and Research (CBER), holds immense promise for patients battling advanced pancreatic cancer, osteosarcoma, soft tissue sarcoma, and breast cancer. The designation of DeltaRex-G, a CCNG1 inhibitor, as a platform therapy with the potential to incorporate other FDA-approved drugs, was enabled by BostonGene's pivotal identification of elevated CCNG1 levels in these different cancer types. Sarcoma Oncology Center, located in Santa Monica, California, is a cancer treatment and clinical research center, recognized for its clinical trials and clinical expertise in treating patients with sarcoma. Sarcomas, rare tumors that originate in bone and connective tissue, pose a unique treatment challenge since most sarcoma subtypes have no approved standard of care treatment and are typically chemotherapy-refractory. The best treatment approach for patients with advanced sarcomas consists of understanding their unique tumor molecular profile, and selection of a therapy that is “matched” to the molecular alterations. Sarcoma Oncology Center partnered with BostonGene for its innovative computational platform, which leverages AI-based molecular and immune profiling. The BostonGene Tumor Portrait™ test uncovers intricate correlations between different “omic” profiles including genomic alterations on tumor cells, profiling of a tumor’s immune landscape, and the potential to use these findings to understand which patients are most likely to benefit from treatment . The authorization of investigational agent DeltaRex-G, a CCNG1 inhibitor, as a platform therapy open to incorporating other FDA-approved drugs and immunotherapies stems from BostonGene's pivotal identification of heightened CCNG1 levels across all tumors tested, including osteosarcoma, soft tissue sarcoma, pancreas, breast, urothelial and testicular carcinoma . " Our partnership with BostonGene provides us with an AI-driven, molecular perspective of the dynamic tumor microenvironment and immune landscape, thereby expanding the treatment horizons for our patients," said Erlinda Gordon, MD. " This collaboration has broadened our cancer treatment options, as BostonGene is the only molecular profiling company reporting on the CCNG1 expression in tumors," said Sant P. Chawla, MD, Director at Sarcoma Oncology Center. “ We are pleased to be working with the Sarcoma Oncology Center to support their efforts in personalizing treatments for their patients. Our advanced sequencing and analytical capabilities will be indispensable in guiding treatment decisions for these cancer patients who would otherwise have very limited options," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. About BostonGene Corporation BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com .